Crohn’s disease in Japanese is associated with a SNP-haplotype of N-acetyltransferase 2 gene

Table 1 Clinical characteristics of study subjects

	Disease
Characteristic	UC	CD	Control
Number of subjects	95	60	200
Age range (yr)	14–83	17–75	20–60
Age (mean±SD)	44.4±16.4b	35.0±12.6	32.5±11.1
Male/female (%)	53 (55.8)/42 (44.2)	35 (58.3)/25 (41.7)	125 (62.5)/75 (37.5)

^bP<0.01 vs control.

Table 2 Distributions of six NAT2-haplotypes in patients with UC/CD and controls

Haplotype	SNP	Number (%) of subjects with haplotype
		UC (allele = 190)	CD (allele = 120)	Control (allele = 400)
NAT2*4	None	122 (64.2)	77 (64.2)	278 (69.5)
NAT2*5B	T341C, C481T, A803G	3 (1.6)	1 (0.8)	2 (0.5)
NAT2*6A	C282T, G590A	43 (22.6)	21 (17.5)	79 (19.75)
NAT2*7B	C282T, G857A	20 (10.5)	18 (15.0)	35 (8.75)
NAT2*11	C481T	0 (0)	1 (0.8)	1 (0.25)
NAT2*13	C282T	2 (1.1)	2 (1.7)	5 (1.25)

Table 3 Comparisons of frequencies of NAT2-haplotypes among study subjects by multiple logistic regression analysis

Haplotype	P	Odds ratio	95% confidence interval
UC patients vs controls
NAT2*4	0.6823	0.809	0.293–2.232
NAT2*6A	0.5621	1.183	0.671–2.084
NAT2*7B	0.3338	1.436	0.689–2.992
CD patients vs controls
NAT2*4	0.2616	2.162	0.563–8.304
NAT2*6A	0.3898	1.349	0.682–2.670
NAT2*7B	0.013	2.802	1.243–6.316

Table 4 Number of subjects with or without haplotype NAT2*7B

NAT2*7B	UC(n = 95, %)	CD(n = 60, %)	Control(n = 200, %)
Presence	19 (20.0)	17 (28.3)	32 (16.0)
Absence	76 (80.0)	43 (71.7)	168 (84.0)

CD patients vs controls: P = 0.032, OR = 2.076.

Table 5 Distributions of three UGT1A7 haplotypes among study subjects

Haplotype	SNP	Number (%) of subjects with haplotype
		UC (allele = 190)	CD (allele = 120)	Control (allele = 400)
UGT1A7*1	None	120 (63.2)	69 (57.5)	242 (60.5)
UGT1A7*2	T387G, C391A, G392A	29 (15.3)	24 (20.0)	55 (13.8)
UGT1A7*3	T387G, C391A, G392A,	41 (21.6)	27 (22.5)	103 (25.7)
	T622C
UGT1A7*4	T622C	0 (0)	0 (0)	0 (0)